Published in Medical Letter on the CDC and FDA, October 19th, 2003
But the U.S. Food and Drug Administration's (FDA)advisers struggled with how much benefit memantine actually offers, and if it could give false hope to families of the most severely ill patients.
"I believe this to be a very small effect size," the panel's chairwoman, Dr. Claudia Kawas of the University of California, Irvine, cautioned. "The entire committee has certain concerns."
When it comes to benefit...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.